Secondary Amyloidosis Development in a Patient with Juvenile Rheumatoid Arthritis on TNF-alpha Inhibitors Treatment

Hong-Ki MIN; Moon-Hee YOON; Eun-Oh KIM; Dae-Won KIM; Nam-Yong KIM; Seung-Ki KWOK; Sung-Hwan PARK; Ho-Youn KIM; Ji-Hyeon JU.
Journal of Rheumatic Diseases ; : 280-284, 2012.
Artículo en Ko | WPRIM | ID: wpr-160529

Documentos relacionados

  1. Macrophage migration inhibitory factor (MIF) and IgA anti CD74 antibodies in Indian patients with enthesitis-related arthritis category of Juvenile idiopathic arthritis.
  2. [Recommendations of diagnosis and treatment of juvenile idiopathic arthritis in China].
  3. [Therapeutic options in juvenile idiopathic arthritis : Surgical and conservative orthopedic rheumatological treatment].
  4. Fifteen-minute guide to managing oligoarticular juvenile idiopathic arthritis.
  5. Mind the Gap: A Longitudinal Analysis of the Experiences of Adolescents and Parents in a Rheumatology Transition Clinic.
  6. T lymphocytes-related cell network in the pathogenesis of juvenile idiopathic arthritis: a key point for personalized treatment.
  7. Paediatric Rheumatology Fails to Meet Current Benchmarks, a Call for Health Equity for Children Living with Juvenile Idiopathic Arthritis, Using Digital Health Technologies.
  8. Exercise programs for scoliosis in juvenile idiopathic arthritis: a randomized-controlled study.
  9. Type I interferon signature as a possible new marker for stratification of patients with juvenile idiopathic arthritis.
  10. Performance of recent PRINTO criteria versus current ILAR criteria for systemic juvenile idiopathic arthritis: A single-centre experience.